Amy Freyman

862 total citations · 1 hit paper
12 papers, 657 citations indexed

About

Amy Freyman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Amy Freyman has authored 12 papers receiving a total of 657 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in Amy Freyman's work include HER2/EGFR in Cancer Research (9 papers), Advanced Breast Cancer Therapies (3 papers) and Biosimilars and Bioanalytical Methods (3 papers). Amy Freyman is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Advanced Breast Cancer Therapies (3 papers) and Biosimilars and Bioanalytical Methods (3 papers). Amy Freyman collaborates with scholars based in United States, Ukraine and China. Amy Freyman's co-authors include Charles Zacharchuk, Lecia V. Sequist, Kwok‐Kin Wong, Susan Quinn, Vincent A. Miller, Keith D. Eaton, Christine Powell, Benjamin Besse, Revathi Ananthakrishnan and Jean‐Charles Soria and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Amy Freyman

12 papers receiving 641 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial

2023 134 citations Brett King, Xingqi Zhang et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amy Freyman United States	7	418	326	263	98	97	12	657
Monica Iorfida Italy	20	662 1.6×	239 0.7×	130 0.5×	21 0.2×	86 0.9×	37	1.1k
Quan Hong United States	13	676 1.6×	257 0.8×	212 0.8×	15 0.2×	134 1.4×	26	941
Sundhar Ramalingam United States	12	287 0.7×	199 0.6×	296 1.1×	19 0.2×	89 0.9×	25	684
Chia‐Chi Lin Taiwan	11	326 0.8×	332 1.0×	187 0.7×	8 0.1×	34 0.4×	25	637
Nobue Kumaki Japan	14	300 0.7×	144 0.4×	135 0.5×	4 0.0×	42 0.4×	47	600
Anne O’Hagan United States	11	423 1.0×	143 0.4×	483 1.8×	5 0.1×	7 0.1×	23	776
Elvire Pons‐Tostivint France	13	468 1.1×	351 1.1×	238 0.9×	11 0.1×	66 0.7×	47	764
B. Lisboa Germany	12	474 1.1×	100 0.3×	203 0.8×	3 0.0×	97 1.0×	23	788
Billie‐Jo M. Kerns United States	12	338 0.8×	139 0.4×	228 0.9×	5 0.1×	67 0.7×	18	592
Xinmin Zhao China	13	354 0.8×	259 0.8×	263 1.0×	3 0.0×	39 0.4×	47	666

Countries citing papers authored by Amy Freyman

Since Specialization

Citations

This map shows the geographic impact of Amy Freyman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Freyman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Freyman more than expected).

Fields of papers citing papers by Amy Freyman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Freyman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Freyman. The network helps show where Amy Freyman may publish in the future.

Co-authorship network of co-authors of Amy Freyman

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Freyman. A scholar is included among the top collaborators of Amy Freyman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Freyman. Amy Freyman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

King, Brett, Xingqi Zhang, Jacek C. Szepietowski, et al.. (2023). A Plain Language Summary on Ritlecitinib Treatment for Adults and Adolescents with Alopecia Areata. Immunotherapy. 15(14). 1093–1103. 4 indexed citations

King, Brett, Xingqi Zhang, Jacek C. Szepietowski, et al.. (2023). Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. The Lancet. 401(10387). 1518–1529. 134 indexed citations breakdown →

Morales, Serafín, et al.. (2021). Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 88(6). 1033–1048. 1 indexed citations

Li, Rubi K., Oleg Lipatov, Hryhoriy Adamchuk, et al.. (2020). Abstract P1-18-08: Trazimera (a trastuzumab biosimilar) in HER2-positive metastatic breast cancer: Long-term safety and overall survival data. Cancer Research. 80(4_Supplement). P1–18. 2 indexed citations

Pegram, Mark D., Igor Bondarenko, Hirotaka Iwase, et al.. (2018). PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. British Journal of Cancer. 120(2). 172–182. 50 indexed citations

Pegram, Mark D., Elizabeth Tan-Chiu, Amy Freyman, et al.. (2017). A randomized, double-blind study of PF-05280014 (a potential trastuzumab biosimilar) vs trastuzumab, both in combination with paclitaxel, as first-line treatment for HER2-positive metastatic breast cancer. Annals of Oncology. 28. v74–v75. 13 indexed citations

Freyman, Amy, Steven D. Reich, Donghua Yin, et al.. (2016). Evaluating imbalances of adverse events during biosimilar development. mAbs. 8(5). 861–866. 2 indexed citations

Chow, Louis WC, Binghe Xu, Sudeep Gupta, et al.. (2013). Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. British Journal of Cancer. 108(10). 1985–1993. 70 indexed citations

Barrios, C.H., A Chan, Suzette Delaloge, et al.. (2011). A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC).. Journal of Clinical Oncology. 29(15_suppl). TPS137–TPS137. 3 indexed citations

10.

Sequist, Lecia V., Benjamin Besse, Thomas J. Lynch, et al.. (2010). Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 28(18). 3076–3083. 357 indexed citations

11.

Gupta, Sumit Kumar, et al.. (2010). Abstract P3-14-04: Efficacy and Safety of Neratinib (HKI-272) in Combination with Paclitaxel in Her2+ Metastatic Breast Cancer. Cancer Research. 70(24_Supplement). P3–14. 7 indexed citations

12.

Chow, Louis W.C., Sudeep Gupta, Dawn L. Hershman, et al.. (2009). Safety and Efficacy of Neratinib (HKI-272) in Combination with Paclitaxel in ErbB2+ Metastatic Breast Cancer.. Cancer Research. 69(24_Supplement). 5081–5081. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact